Fulcrum Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $80.0M | $2.8M | $6.3M | $19.2M |
| Operating income | -$84.8M | -$21.9M | -$110.7M | -$112.6M | -$81.1M |
| Operating expenses | $84.8M | $101.9M | $113.5M | $118.9M | $100.2M |
| Cash from operations | -$60.1M | -$2.2M | -$91.0M | -$97.0M | -$78.5M |
| Capital expenditure | $314,000 | $278,000 | $508,000 | $2.0M | $1.7M |
| Free cash flow | -$60.4M | -$2.5M | -$91.5M | -$99.0M | -$80.2M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $366.3M | $260.7M | $257.7M | $226.7M | $235.0M |
| Total liabilities | $17.3M | $17.7M | $22.5M | $27.7M | $23.5M |
Shares outstanding 66.6M · Free float 79.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.